F-box and WD repeat domain-containing protein 7 (FBW7), also known as FBXW7, AGO or hCDC4, is an F-box protein with seven tandem WD40 repeats. FBW7 is a key substrate recognition subunit of the Skp1-Cul1-F-box-protein E3 ubiquitin ligase. FBW7 targets for ubiquitination and destruction of numerous crucial transcription factors and protooncogenes, including cyclin E, c-Myc, c-Jun, Notch and MCL-1. FBW7 is a well-characterized tumor suppressor, and its gene is frequently mutated or deleted in various types of human cancer, including colorectal cancer, gastric cancer, ovarian cancer and different types of leukemia. Accumulating evidence indicates that the aberrant expression of FBW7 is involved in the development of hematological tumors, including T cell acute lymphoblastic leukemia, adult T cell leukemia/lymphoma, chronic lymphocytic leukemia and multiple myeloma. The present review will describe the latest findings on the role of FBW7 in hematological tumors, in order to identify a novel target for future therapies.
Introduction
The ubiquitin-proteasome system (UPS) is the major regulatory pathway of protein degradation in eukaryotic cells (1) . Defects in UPS function can result in several diseases, including cancer (2) . F-box and WD repeat domain-containing protein 7 (FBW7), also known as FBW7, AGO or hCDC4, is an essential component of the Skp1-Cul1-F-box (SCF)-type ubiquitin ligase (E3) complex, which comprises four subunits: Skp1, cullin1, Rbx1 and an F-box protein that determines substrate specificity (3) . FBW7 is a member of the F-box protein family (4) . Previous studies demonstrated that dysregulation of FBW7 serves a crucial role in the development of hematological tumors (5-7) ( Fig. 1 ).
Structure and activity of FBW7
The human FBW7 gene is located on chromosome 4 (4q31.3) and encodes three transcripts named FBW7α, FBW7β and FBW7γ (8) . The corresponding three proteins possess identical catalytic function but distinct subcellular localizations. FBW7α is mostly localized in the nucleus, whereas FBW7β is found in the cytoplasm and FBW7γ in the nucleolus (9) . These three subtypes have different amino acid sequences in the N-terminal region but contain conserved interaction regions (F-box and WD40 repeats) in the C-terminal region (9) (10) (11) . All isoforms share three essential domains that have distinct functions: i) D domain; ii) F-box domain and iii) seven tandem WD40 (tryptophan-aspartic acid 40) repeats (9) (Fig. 2) . The D domain promotes FBW7 dimer-
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QIAOJUAN ZHU 1* , LINJUN HU 2* , YANG GUO 3 , ZUNQIANG XIAO 4 , QIURAN XU 5 and XIANGMIN TONG 5 ization and facilitates its binding to substrates (9) . The F-box domain is necessary for direct binding of FBW7 to Skp1, enabling the recruitment of other components of SCF (9) . The WD40 repeats are required for substrate recognition (12) .
The target proteins degraded by FBW7 contain a conserved sequence of phosphorylated amino acids named CDC4 phosphodegron (CDP). CDPs bind to the WD40 repeats, allowing the recognition of the substrate by ubiquitin ligase for its subsequent degradation (10) . Furthermore, dimerization of FBW7 increases the binding of FBW7 to substrates, particularly to those with weak phosphodegrons (13) . In addition, glycogen synthase 3β (GSK3β) serves a crucial role in the degradation of substrate by FBW7. GSK3β catalyzes the phosphorylation of threonine in the substrate CDPs, promoting FBW7 binding and accelerating the degradation of the substrate (14,15) ( Fig. 2 ).
Substrates of FBW7 in cancer
FBW7 is an important substrate adaptor responsible for recognition and binding of the substrate proteins in the ubiquitin-proteasome degradation pathway. Many of its substrates are oncogenes. For example, c-Myc is an important substrate for ubiquitination by FBW7 (16, 17) .
In general, decreased expression of FBW7 results in a significant increase in the intracellular content of c-Myc protein, whereas overexpression of FBW7 promotes c-Myc ubiquitination and degradation, decreasing its cellular level (14) . In the Burkitt's lymphoma cell line, c-Myc is most commonly mutated at T58, causing the failure of FBW7 to regulate c-Myc protein degradation, ultimately leading to c-Myc protein accumulation and tumorigenesis (14) . Cyclin E is another classical substrate of FBW7. By binding to cyclin E-dependent kinase 2 (CDK2), cyclin E forms a complex that promotes the G/S phase transition, leading to uncontrolled cell proliferation (18) . FBW7 can also ubiquitinate various other target proteins, including Notch1 (19) , NF-κB (20) , c-Jun (21), granulocyte colony stimulating factor receptor (22) , SHOC2 leucine rich repeat scaffold protein (23), brahma-related gene-1 (24), Aurora A (25), Kruppel like factor 5 (26), heat shock transcription factor 1 (27) and CCAAT/enhancer-binding protein α (28) (Table I) .
Regulation of FBW7
The main mechanisms of FBW7 disruption in cancer are deletion, mutation and promoter methylation (29) (30) (31) and the gene mutation is the most common. A previous study demonstrated that FBW7 is mutated in ~6% of human tumors, and in 31% Figure 1 . Ubiquitin-proteasome system and FBW7 (monomeric and dimeric) degrading specific substrate. (A) E1 activates Ub protein that is transferred to the cysteine residue of E2 to form the E2-Ub complex. Subsequently, in a step catalyzed by E3, Ub covalently binds to the target protein, forming a polyubiquitin chain. The ubiquitinated protein is recognized by the 26S proteasome and degraded in an ATP-dependent manner. (B) FBW7 is present as a monomer and a dimer. Dimerization of the FBW7 protein enhances the activity and the binding of FBW7 to substrates, particularly to substrates with weak CDC4 phosphodegron, including cyclin-dependent kinase inhibitor Sicl. However, certain protein substrates, including cyclin E and c-Myc, can be efficiently degraded by monomeric FBW7. Cul1, cullin1; FBW7, F-box and WD repeat domain-containing protein 7; P, phosphorus; Rbx1, ring-box 1; Skp1, S-phase kinase associated protein 1; Ub, ubiquitin; E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; E3, ubiquitin ligase of acute T-cell lymphocytic leukemia cases (32) . It has been demonstrated that conditional FBW7 knockout in the T-cell lineage of mice leads initially to thymic hyperplasia and subsequently to the development of thymic lymphoma, indicating that the loss of FBW7 function is an important factor responsible for tumorigenesis in the blood system (33) . In addition, FBW7 expression and activity can be regulated by numerous genes, including p53 (34) . FBW7 is a p53-depen-dent tumor suppressor, and p53 activation can enhance the ubiquitination-mediated degradation of oncoproteins (34) . Furthermore, previous studies have identified numerous micro (mi)RNAs that can regulate FBW7 expression, including miR-223 (35) , miR-25 (36) , miR-182 (37), miR-503 (37) and miR-92a (38) . In addition, in T-cell acute lymphoblastic leukemia (T-ALL), miR-223 acts as an oncogene by inhibiting the FBW7 expression. The expression of FBW7 is also controlled by the RBP-J-interaction and tubulin-associated (RITA) protein. Overexpression of RITA results in increased expression of FBW7 and decreased expression of cyclin E, cyclin D1, CDK2, Hes-1 and NF-kBp65 (39) . In addition, NF-κB1 (40), Pin1 (41), family with sequence similarity 83 member D (FAM83D) (42) and Numb4 (43) are also regulators of FBW7 expression (Table II) .
FBW7 mRNA expression in different types of human cancer
In order to determine whether FBW7 is differently expressed in tumor tissues compared with normal tissues, the Oncomine database (https://www.oncomine.org) was used to analyze FBW7 mRNA levels in different tumor and normal tissues. The results indicated that FBW7 expression is higher in leukemia ( Fig. 3A ), suggesting that FBW7 may be associated with the initiation and progression of certain hematological tumors. The Timer database (https://cistrome. shinyapps.io/timer/) was then used to analyze FBW7 mRNA levels in diffuse large B cell lymphoma (DLBCL). The result demonstrated no significant difference in FBW7 expression level in DLBCL. This may be due to different expression levels of FBW7 in various hematological tumors ( Fig. 3B ).
Role of the FBW7 gene in common hematological tumors
T-ALL. T-ALL is a highly proliferative hematologic malignancy caused by the malignant transformation of T-cell progenitors (44) . Patients with T-ALL typically present with aggressive clinical features correlated with poor prognosis, including inhibition of normal hematopoietic function, high white blood cell counts, pleural effusions and central nervous system involvement (45) . T-ALL accounts for 15 and 25% of the total number of childhood and adult cases of acute lymphoblastic leukemia, respectively (46) . The rate of T-ALL complete remission can reach 94%, and the long-term survival rate can be as high as 85% (47); however, 20% pediatric patients and 40% adult patients are prone to recurrence and ultimately develop refractory leukemia (48) . Understanding the underlying mechanisms of T-ALL development is therefore critical. T-ALL is the only known malignant cancer that can be induced by FBW7 deletion without the requirement of other tumor-promoting factors (49, 50) . Furthermore, T-ALL development is accelerated by the simultaneous loss of p53 or Phosphatase and TENsin homolog or by concurrent activation of Notch (49, 51, 52) . However, it was demonstrated that FBW7 hotspot mutation knock-in mice (FBW7 mut/+ ) do not develop spontaneous leukemia, suggesting that the FBW7 missense mutation and FBW7 homologous deletion present subtle differences (53) . FBW7 deletion/mutation increases the protein level of Notch and c-Myc (49,50,53,54). However, Notch1 alone is not sufficient to induce or maintain T-ALL in the absence (53) . It was reported that >60% of T-ALL cases present with abnormal activation of the Notch1 signaling pathway, indicating that Notch1 might be the most common oncogene in T-ALL (55) . Mutations of Notch1 occur mainly in the heterodimeric domain region and the proline, glutamine, serine, and threonine domain (56, 57) . Activating mutations of Notch1 gene result in sustained expression of genes regulating T cell differentiation, including Hes family bHLH transcription factor 1 and CD25, changing the expression balance of c-Myc and p27 (58) (59) (60) , upregulating the NF-κB signaling pathway (5), enhancing the expression of the anti-apoptotic X-linked inhibitor of apoptosis protein associated with ubiquitination and degradation, and activating the PKB/Akt/mTOR signaling pathway-mediated inhibition of p53 (61) . All the aforementioned signaling pathways inhibit apoptosis and cause abnormal proliferation of non-functional T cells, thereby directly leading to the development of T-ALL. In addition, Notch and NF-κB bind to the promoter of miR-223, activating its expression (62) . Notch-mediated upregulation of miR-223 subsequently inhibits FBW7 gene expression in T-ALL, and miR-223 and FBW7 expression are negatively correlated in T-ALL patient-derived xenografts (62) . In addition, it has been demonstrated that FBW7 loss of function leads to an upregulation of the glucocorticoid receptor in primary T-ALL cells, thereby enhancing their sensitivity to glucocorticoids and improving the prognosis of patients with T-ALL (63). MCL-1 is an anti-apoptotic protein of the BCL-2 family that promotes cancer by inhibiting apoptosis (64) . Deletion of FBW7 in T-ALL cell line results in an increased expression level of MCL-1. MCL-1 upregulation is sensitive to various kinase inhibitors, including sorafenib, but resistant to the BCL2 inhibitor ABT-737. However, when FBW7 function is restored or MCL-1 is deleted, cell sensitivity to ABT-737 is restored (65) . MCL-1 also serves a role in the chemotherapy efficacy of anti-tubulin drugs. Treatment with paclitaxel and similarly acting compounds induces MCL-1 phosphorylation, which is then recognized by FBW7 and degraded by ubiquitination. Subsequently, the intracellular MCL-1 protein content is significantly decreased and promotes therefore apoptosis. In addition, when FBW7 is inactivated or downregulated in the tumor, the stability of MCL-1 protein is enhanced, thereby increasing resistance of the tumor to microtubule-targeted drugs and decreasing the effectiveness of chemotherapy (66) . The cellular content of MCL-1 protein is also affected by the deubiquitinating enzyme named ubiquitin specific peptidase 9 X-Linked (USP9X) (67) . Since USP9X decreases the ubiquitination of MCL-1 and increases its stability, USP9X downregulation and decreased MCL-1 protein expression could increase tumor cell sensitivity to ABT-737 treatment.
Adult T cell leukemia/lymphoma (ATL)
. ATL is a malignant T cell monoclonal proliferative disease caused by the human T-cell leukemia virus type 1 (HTLV-1). ATL represents a rare type of lymphocytic leukemia/lymphoid tumor affecting T cells (68) . FBW7 acts as a tumor suppressor in ATL cells; however mutations can transform FBW7 into an oncogenic protein (69) . Mutations in the WD40 domain of FBW7 were identified in 25% (8/32) of acute ATL cases (69) . Furthermore, the FBW7 D510E and D527G mutants are capable of ubiquitinating proteolysis of endogenous cyclin E, MCL-1, and c-Myc. However, these mutants are ineffective in degrading the Notch intracellular domain (NICD) in ATL cells, resulting in the activation of Notch1 signaling. The increased Notch1 signaling can subsequently promote ATL cell proliferation and tumorigenesis (69) . The same mutants present significant carcinogenic activity when co-expressed with HTLV-1 Tax, mutated p53 R276H or c-Myc38C (69). In addition, previous studies reported the downregulation of FBW7 expression in ATL, which leads to c-Myc accumulation and initiation of ATL cell proliferation (70) . The c-Myc-FBW7 axis pathway could therefore represent a potential target for the treatment of ATL.
Chronic lymphocytic leukemia (CLL). CLL is the most common type of leukemia in Western countries (71) . CLL is primarily characterized by the accumulation of monoclonal CD5 + mature B cells in lymphoid tissues and peripheral blood (72) . Despite significant advances in its treatment, CLL remains incurable (73) . In CLL, the mutation rate of FBW7 is 2-6% (74-76), and these mutations are associated with chromosome 12 trisomy aberrations of mature CD19 + B cells (75) . A previous study identified FBW7 mutations in 36 out of 905 untreated patients with CLL. All these mutations are heterozygous, missense in 78% of cases and primarily affect the substrate-binding domain of WD40 (77) . Furthermore, 10% of the mutations were located on the first exon of the α-transcript. In order to identify the target protein of FBW7 in CLL, a WD40 domain-truncated CLL cell line (HG-3) was generated using the CRISPR/Case9 method (77) . Homozygous truncation of FBW7 results in increased levels of activated Notch1-NICD and c-Myc proteins, and in enhanced activity of HIF1-α (77) . In primary cells derived from patients with CLL carrying the FBW7 mutation, the level of activated Notch1-NICD was elevated and remained stable after inhibition of translation (77) . In addition, FBW7 mutation was combined with enhanced expression of Notch1 target genes (77) . FBW7 mutations in CLL cells may therefore explain the dysregulation of Notch1 signaling in certain patients with CLL, indicating that FBW7 could be a cancer-driving gene in CLL.
Multiple myeloma (MM). MM, which is an incurable malignant plasma cell disease, is one of the most common hematological malignancies in adults, accounting for 15% of malignant hematological tumors (78) . MM is primarily characterized by clonal proliferation and abnormal accumulation of plasma cells in the bone marrow, combined with the secretion of a large number of monoclonal immunoglobulins (79) . The etiology of MM is complex. NF-κB may serve a crucial role in supporting MM cell survival. The NF-κB signaling pathway is activated in the majority of patients with MM, whereas NF-κB signaling pathway blockage using some inhibitors of NF-κB kinase subunit β (IKK2) can inhibit MM cell proliferation (80, 81) .
In non-canonical NF-κB pathway, IKKα is activated by NIK and directly phosphorylates p100. Phosphorylated p100 is therefore degraded in a 26S proteasome-dependent manner (82) . It has been demonstrated that p100 degradation in the nucleus is crucial to activate the non-canonical NF-κB pathway (83) . During this reaction, FBW7 recognizes the CPD sequence of p100 and promotes p100 degradation in a GSK-3 phosphorylation-dependent manner (15) . Furthermore, FBW7 overexpression enhances the activity of NF-κB, whereas FBW7 downregulation can upregulate p100 expression (15) . In MM, FBW7 silencing leads to an increased expression of p100 and partly activates MM cell apoptosis (15, 84) . FBW7 may therefore be an oncogene in MM. In addition, fibroblasts from patients with MM are crucial in the progression of the disease and in drug resistance (85, 86) . For example, it was demonstrated that miR-27b-3p is significantly upregulated in the fibroblasts of bone marrow from patients with MM where it controls FBW7 activity, which in turn regulates MCL-1 that can promote fibroblast proliferation (87).
Conclusions and perspectives
FBW7 is an important tumor suppressor that regulates multiple oncogenes, including cyclin E, c-Myc, Notch, c-Jun and mTOR. In addition, FBW7 is regulated by p53, certain miRNAs, including miR-223, miR-25, miR-182, miR-503 and miR-92a, RITA, FAM83D and Numb4. Mutation, deletion and hypermethylation are the main mechanisms of FBW7 disruption in cancer, leading to tumor progression. Mutation of FBW7 may promote tumorigenesis and increase the tumor resistance to chemotherapy. Furthermore, the carcinogenic effects of FBW7 have also been identified in certain types of hematological tumor, including ATL and MM. These findings have important implications for the understanding of hematopoietic mechanisms, development of diagnostic reagents, and design and optimization of therapeutic drugs. The detection of FBW7 mutations is clinically relevant, and FBW7 could serve as a potential target for the treatment of hematological tumors. Further investigation into FBW7 mutations will have a positive impact on the prevention of hematological tumors and the development of personalized treatments.
